Skip to main content
Displaying 92 of 2909 articles.
A treatment that appears effective in cancers such as myelofibrosis consistently fails in breast cancer clinical trials. A new study explains why.

New findings describe how the enzyme CST is recruited to the end of the telomere, where it maintains telomere length with the help of subtle chemical changes made to the protein POT1.

The end replication problem dictates that telomeres shrink unless telomerase intervenes. But the problem is actually twice as complicated, with telomerase providing only part of the solution.

Telomerase could run amok, deleteriously capping damaged DNA, were it not for a first responder to DNA damage.

Marraffini is honored for his pioneering research on the study of CRISPR-Cas systems.

Birsoy is honored for groundbreaking research uncovering metabolic weaknesses of diseased cells, such as cancer, while shedding light on debilitating mitochondrial diseases and rare genetic disorders.

Researchers have long disagreed over whether ??T cells in the gut promote or discourage tumor growth, but new evidence suggests they have the capacity to do both.

She receives the honor for elucidating mechanisms of telomere protection and genome maintenance.

Unlike conventional antiretroviral drugs, treatment with broadly neutralizing antibodies does not rely on vigilant daily dosing and could potentially reduce the body’s reservoir of latent viruses.

Birsoy's groundbreaking research has highlighted key nutrients that cancer cells need to survive, while shedding light on debilitating mitochondrial diseases and rare genetic disorders.
View
View